Revolution Medicines, based in Redwood City, California, revealed that they will showcase four oral and poster presentations at the 2026 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Munich, Germany from July 1 to 4. The company, specializing in targeted therapies for individuals with RAS-addicted cancers, will feature data from its RAS(ON) pipeline during the event. This significant announcement was made on June 24, 2026.